Overview

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma

Status:
Not yet recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
A two-arm, randomised trial investigating the response of encorafenib and binimetinib compared to standard adjuvant therapy.
Phase:
Phase 2
Details
Lead Sponsor:
CCTU- Cancer Theme
Collaborator:
Pierre Fabre Medicament